PDE10A: cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides.
- Drugs that act on it: 4
- Approved: 1
- In phases 1 to 3: 3
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on PDE10A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- MediciNova125%
- Palobiofarma SL125%
- Pfizer125%
- Takeda Pharmaceuticals USA125%
| Ibudilast | Approved | MediciNova | Small molecule | Inhibitor | 2 |
| Balipodect | Phase 2 | Takeda Pharmaceuticals USA | Small molecule | Inhibitor | 0 |
| Mardepodect | Phase 2 | Pfizer | Small molecule | Inhibitor | 0 |
| PBF-999 | Phase 1 | Palobiofarma SL | Small molecule | Inhibitor | 0 |
| Ibudilast for Treating Alcohol Use Disorder | Ibudilast | Phase 2 | Active, not recruiting | University of Pennsylvania | Jun 10, 2022 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | Ibudilast | Phase 2 / Phase 3 | Active, not recruiting | MediciNova | Aug 15, 2019 |
- Infantile-onset generalized dyskinesia with orofacial involvement0.75
- Striatal degeneration, autosomal dominant 20.69
- Stroke disorder0.55
- Hypothyroidism0.55
- Coronary artery disorder0.54
- Hypertensive disorder0.53
- Cardiovascular disorder0.52
- Thyroid gland disorder0.52
- Hyperthyroidism0.52
- Striatal degeneration, autosomal dominant0.48
- Intermittent vascular claudication0.43
- Autoimmune thyroid disease0.41
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4409, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9Y233, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets